The
global Advanced
Therapy Medicinal Products CDMO Market size is expected to reach USD 18.8
billion by 2030, according to a new report by Grand View Research, Inc. The
market is expected to register a CAGR of 18.8% from 2023 to 2030, owing to
rising clinical trials for advanced therapy medicinal products and
the increasing awareness among researchers about the benefits of advanced
therapies, driving the advanced therapy medicinal products (ATMP) CDMO market
growth. Tissue engineering has greatly benefited in recent years from
technological development. The damaged tissues and organ function are replaced
or restored using this technique. Similarly, gene and cell therapy are
attracting a lot of patients for the treatment of rare diseases, whose incidence
is rising globally.
With
rising demand for robust disease treatment therapies, key players have focused
their efforts to ramp up research and development for effective gene therapies
that target the cause of disorder at a genomic level. According to ASGCT, the
number of cell and gene therapies in the U.S. pipeline programs (phase I-III
trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA
delivers constant support for innovations in the gene therapy field via a
number of policies with regard to product manufacturing. In January 2020, the
agency released six final guidelines on the manufacturing and clinical
development of safe & efficient gene therapy products.
Moreover,
awareness about ATMP treatment options is being driven by initiatives aimed at
informing the public about the benefits of these products, which, in turn, is
leading to increased adoption of advanced therapies and fueling market growth
for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell
and Gene Medicine prioritizes activities for increasing public awareness
through educational programs, underlining the clinical & societal benefits
of regenerative medicine.
Increasing
clinical trial activity along with new product launches generates growth opportunities
for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535
are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved
six of these additional ATMPs, and five more will be approved by 2023. In the
UK, there were approximately 168 advanced therapy medicinal product trials
underway in 2021, up from the 154 studies reported the year before, which is a
9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a
significant shift from experimental medicines to first-in-human studies.
On
the other hand, key players are undertaking various strategic initiatives to
introduce novel products, which is expected to propel market growth. For
instance, in March 2021, CureVac N.V. signed a partnership agreement with
Celonic Group, engaged in the manufacture of CVnCoV, CureVac’s mRNA-based
COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is
manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics
in Heidelberg, Germany. Under the terms of the commercial supply agreement, the
Celonic facility could produce over 100 million doses of CVnCoV.
Related
Press Release@ Advanced Therapy Medicinal Products
CDMO Market Report
Advanced Therapy Medicinal Products CDMO Market Report
Highlights
- By product,
gene therapy accounted for a major share of market space due to increasing
clinical trials for gene therapies. Moreover, collaborative efforts for
the development of novel gene therapies and the resultant expansion in gene
therapy applications are factors expected to drive the volume of
manufacturing
- Cell
therapy is expected to account for a significant market share in the
coming years. A rise in research interests and the adoption of advanced
cell therapies are attracting increased investments. The segment is being
driven by CDMOs attracting investments to keep up with growing commercial
markets and support their growth and diversification prospects
- By phase,
the phase I segment dominated the market revenue share in 2022. This is
attributed to the growing number of human trials for advanced therapies
and rising R&D activities
- By
indication, the oncology segment held a major share of the market in 2022
due to the increasing number of cancer patients and increasing cell and gene
therapy research related to cancer. Moreover, technological advancements,
such as the development of cancer vaccines, are expected to further
support segment growth
- North
America dominated the global market in 2022, owing to increasing
healthcare expenditure and the presence of key players. Companies such as
Novartis AG, Sanofi, Johnson & Johnson Services, Inc., and Viatris are
positively influencing market growth
- For
instance, in June 2022, Novartis AG launched Dimethyl fumarate HEXAL for
the treatment of patients with Relapsing-Remitting Multiple Sclerosis
(RRMS) in Germany. This strategic launch was aimed at commercializing
Hexal in Germany
- The Asia
Pacific region is expected to expand considerably in the future. China is
one of the major markets in the region. The market growth can be
attributed to increasing government investments and reforms in policies
related to the manufacturing of pharmaceutical products. China ranked
second in the world for cell & gene therapy development with more than
1,000 clinical trials conducted in the country
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment